Financial performance of pharmaceutical companies in the Philippines calendar year 2016 Jhon Sean B .Agosto, Eladia A. De Mesa,Delma Grace L. Quilonio

Thesis BSA University of Rizal System, Binangonan 2017

includes bibliographical references

This study aims to determine the financial performance of Pharmaceutical Companies in the Philippines Calendar Year 2016. The researchers used the descriptive method of research. No interviews were conducted and the sources of information are limited to the audited financial statements of Abbott Laboratories, AstraZeneca Pharmaceuticals (Phil) Incorporated, GlaxoSmithKline Philippines Incorporated Pfizer Incorporated, and Novartis Health Care Phil. Incorporated The researchers used financial ratio as to profitability and operating efficiency, liquidity, and financial leverage to evaluate the financial performance of each company. Based on the presentation, interpretation, and analysis of the data gathered, the researchers found out and conclude that in terms of the Year of existence, the longest in operation among the five companies is Abbott Laboratories for 66 Years, followed by Pfizer for 61 Years, GlaxoSmithKline for 48 Years, Novartis Healthcare for 18 Years and AstraZeneca for 16 Years. In terms of the aggregate capital for the Year 2012-2015, Pfizer has the highest capital, followed by Abbott Laboratories, GlaxoSmithKline, Novartis Healthcare, and AstraZeneca. In terms of financial ratios calculated, it has a great discrepancy from company to company. Based on the summary findings and conclusion; Abbott Laboratories, should minimized its operating expenses and total debt, and increase its liquid assets. AstraZeneca, should minimized its operating expenses and total debt. GlaxoSmithKline, should negate its cost of sales, minimize its operating and other expenses, increase its current and liquid assets, and minimize its total debt. Novartis Healthcare, should minimize its cost of sales and operating expenses, retain its improving financial situation and sustain its decreasing total debt. Pfizer, should sustain its good profitability and liquidity condition and minimize its total debt. In general, Pharmaceutical Companies should focus on the policies and strategies of management and insight into its future performance, how to survive in its operating environment, how to provide investment attractive returns, and should focus on how cash flows be sufficient to meet short term and long term obligations.